6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Harmonizing allergy care–integrated care pathways and multidisciplinary approaches

      review-article
      , BSc a , , , BSc a , , , MD, PhD b , , MD, PhD c , , PhD d , e , , BComm f , , MD, PhD g , , MB. ChB, MD h , i , , MD j , , MD, MHA j , , MSc k , , MD, PhD l , , MD e , , MD m , , MD n , , MD j , , MD, PhD o , p , , MD q , , MBBS, MRCPCH r , s , t , , PhD, RD u , , MD, PhD j , , MD, PhD v , , , DO w , , , MD, PhD e , x , y , , , MD z , ,
      The World Allergy Organization Journal
      World Allergy Organization
      Allergy, Integrated care pathways, Multidisciplinary team, Healthcare

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is a wide time gap between the publication of evidence and the application of new knowledge into routine clinical practice. The consequence is sub-optimal outcomes, particularly concerning for long-term relapsing/remitting conditions such as allergic diseases. In response, there has been a proliferation of published guidelines which systematically review evidence for the gold-standard management of most allergic disorders. However, this has not necessarily been followed by improved outcomes, partly due to a lack of coordination across the patient pathway. This has become known as the "second translational gap". A proposed solution is the development and implementation of integrated care pathways (ICPs) to optimize patient outcomes, with the notion that evidence-based medicine requires evidence-based implementation. ICP implementation is shown to improve short-term outcomes for acute conditions and routine surgery, including reduced length of hospital stay, improved documentation and improved patient safety. However, this improvement is not reflected in patient experience or patient-centered functional outcomes. The implementation of life-long, cost-effective interventions within comprehensive pathways requires a deep appreciation for complexity within allergy care.

          We promote an evidence-based methodology for the implementation of ICPs for allergic disorders in which all stakeholders in allergy care are positioned equally and encouraged to contribute, particularly patients and their caregivers. This evidence-based process commences with scoping the unmet needs, followed by stakeholder mapping. All stakeholders are invited to meetings to develop a common vision and mission through the generation of action/effect diagrams which helps build concordance across the agencies. Dividing the interventions into achievable steps and reviewing with plan/do/study/act cycles will gradually modify the pathway to achieve the best outcomes. While the management guidelines provide the core knowledge, the key component of implementation involves education, training, and support of all healthcare professionals (HCPs), patients and their caregivers.

          The pathways should define the level of competence required for each clinical task. It may be useful to leave the setting of care delivery or the specific HCP involved undefined to account for variable patterns of health service delivery as well as local socioeconomic, ethnic, environmental, and political imperatives. In all cases, where competence is exceeded, it is necessary to refer to the next stage in the pathway. The success and sustainability of ICPs would ideally be judged by patient experience, health outcomes, and health economics. We provide examples of successful programs, most notably from Finland, but recommend that further research is required in diverse settings to optimize outcomes worldwide.

          Related collections

          Most cited references82

          • Record: found
          • Abstract: found
          • Article: not found

          Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision.

          Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

              Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally. To develop explicit, unambiguous, and transparent clinical recommendations systematically for treatment of allergic rhinitis on the basis of current best evidence. The authors updated ARIA clinical recommendations in collaboration with Global Allergy and Asthma European Network following the approach suggested by the Grading of Recommendations Assessment, Development and Evaluation working group. This article presents recommendations about the prevention of allergic diseases, the use of oral and topical medications, allergen specific immunotherapy, and complementary treatments in patients with allergic rhinitis as well as patients with both allergic rhinitis and asthma. The guideline panel developed evidence profiles for each recommendation and considered health benefits and harms, burden, patient preferences, and resource use, when appropriate, to formulate recommendations for patients, clinicians, and other health care professionals. These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Journal
                World Allergy Organ J
                World Allergy Organ J
                The World Allergy Organization Journal
                World Allergy Organization
                1939-4551
                25 September 2021
                October 2021
                25 September 2021
                : 14
                : 10
                : 100584
                Affiliations
                [a ]Faculty of Medicine, Imperial College London, London, UK
                [b ]Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
                [c ]Department of Immunology, Tbilisi State Medical University, Tbilisi, Georgia
                [d ]Applied Psychology and Paediatrics and Child Health, University College Cork, Cork, Ireland
                [e ]Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
                [f ]Food Allergy Canada, Toronto, ON, Canada
                [g ]Section of Allergology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
                [h ]Association for Medical Education in Europe (AMEE), Dundee, Scotland, UK
                [i ]Independant Consultant in Primary Care and Medical Education, UK
                [j ]Regional Center of Allergy and Clinical Immunology, University Hospital “Dr. Jose Eleuterio Gonzalez”, Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico
                [k ]Imperial College London, London, UK
                [l ]Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt
                [m ]Health Sciences Center, Autonomous University of Hidalgo State, Mexico
                [n ]Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand
                [o ]Asthma, Allergy and Immune Dysfunction Clinic, Twin Palms Medical Centre, Harare, Zimbabwe
                [p ]Department of Pathology, Medical School, National University of Science and Technology, Bulawayo, Zimbabwe
                [q ]Division of Allergy and Immunology, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
                [r ]Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
                [s ]Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, National University Health System, Singapore, Singapore
                [t ]Human Potential Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
                [u ]Section of Allergy and Immunology, University of Colorado Denver School of Medicine, Children's Hospital Colorado, Colorado, USA
                [v ]Division of Paediatric Allergy, Department of Paediatrics, University of Cape Town, Cape Town, South Africa
                [w ]Division of Allergy and Immunology, Department of Otolaryngology, The Ohio State University, Columbus, OH, USA
                [x ]Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK
                [y ]Solov'ev Research and Clinical Center for Neuropsychiatry, Moscow, Russia
                [z ]Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK
                Author notes
                []Corresponding author. Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, SW3 6LY, UK. j.o.warner@ 123456imperial.ac.uk
                [†]

                These authors contributed equally to this manuscript.

                Article
                S1939-4551(21)00078-8 100584
                10.1016/j.waojou.2021.100584
                8591185
                34820045
                9b6595e0-1fbb-4819-8c83-40632e745b60
                © 2021 Published by Elsevier Inc. on behalf of World Allergy Organization.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 1 February 2021
                : 8 August 2021
                : 26 August 2021
                Categories
                Article

                Immunology
                allergy,integrated care pathways,multidisciplinary team,healthcare
                Immunology
                allergy, integrated care pathways, multidisciplinary team, healthcare

                Comments

                Comment on this article